Is Mounjaro on the PBS? Not for any indication, and here is why.

Neither. Mounjaro is not PBS-subsidised for type 2 diabetes, for weight management, or for obstructive sleep apnoea.

The current Australian Consumer Medicine Information (CMI) lists three uses for Mounjaro KwikPen: type 2 diabetes in adults and in children and adolescents aged 10 and over weighing at least 50 kg; weight management in adults with overweight or obesity; and moderate-to-severe obstructive sleep apnoea in adults with obesity. Being registered by the Therapeutic Goods Administration (TGA) for a use is a separate step from being subsidised for it. A medicine can be approved as safe and effective and still not be on the PBS.

The only tirzepatide use that reached a positive PBAC recommendation was type 2 diabetes, and that recommendation did not become a listing. So, as of October 2026, people prescribed Mounjaro for any reason get it on a private prescription. We do not publish medicine prices; a pharmacist can tell you what a private prescription costs.

Lilly said the price and funding conditions attached to the listing were not workable for the company. A PBAC recommendation is not the end of the process: the sponsor and the Government still have to agree terms before a medicine is listed.

As reported by RACGP newsGP on 28 April 2026, Lilly said the Government's price conditions were "unrealistic and unviable", and that the price was "significantly lower than any other reimbursed price globally". It cited funding caps that it said put "disproportionate financial risk" on Lilly, and said the decision affects up to 450,000 Australians with type 2 diabetes. Trade press, including the limbic (29 April 2026) and Pharmacy Daily, also reported funding caps and wholesaler margins among the issues.

These are the company's stated reasons. The Government's side of the negotiation is not set out in the sources we checked, so this page does not characterise it. For context on how the process works, our Is Wegovy on the PBS? explainer walks through the steps from PBAC recommendation to listing.

It means a private prescription, with the full price paid by the patient, whatever the reason for prescribing. The PBS status does not change what the TGA has approved Mounjaro for, or the dosing set out in the Australian Product Information.

Two practical points follow from the sources. First, the type 2 diabetes recommendation does not help anyone today: until a medicine is actually listed, a PBAC recommendation has no effect on what a patient pays. Second, PBS status can change. The record for tirzepatide was updated as recently as 30 September 2026, and the PBAC has looked at tirzepatide four times since July 2023, so it is worth checking the PBS medicine status page rather than relying on older articles or social media posts.

If cost or access is a concern, that is a conversation for your prescriber, who can explain the options registered and subsidised for your situation. Other GLP-1 receptor agonists, Ozempic (semaglutide) and Trulicity (dulaglutide), remain PBS-listed for type 2 diabetes. Preptide does not recommend any medicine over another. Our weight-loss medication in Australia overview and GLP-1 medicines in Australia guide set out the registered options neutrally.

Food is not a substitute for any medicine, and no food changes how a medicine works. The PBAC itself called for better access to diet and physical-activity support alongside medicines.

For people whose appetite has changed, many find smaller, protein-forward meals easier to manage. Our GLP-1 meal plan, portion guide and protein guide are general food information, written to sit alongside the advice of your prescriber or dietitian.